Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Contraception (Estradiol with nomegestrol - Contraception)

Records returned : 37 (on 01 Jun 2025 at 15:57:05). Return to search results for ' Contraception '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
1.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Not recommended for new initiations. Existing patients may remain on this brand.

 
Links :
Indication :
Status :
Green
Formulations :
  • Intrauterine device (copper)
Restrictions / Comments:

Important
Preferred

Copper T380 A®

 
Links :
Indication :
Status :
Green
Formulations :
  • Intrauterine device (copper)
Restrictions / Comments:

Important

Nova T 380

 
Links :
Indication :
Status :
Green
Formulations :
  • Intrauterine device (copper)
Restrictions / Comments:

Important
Preferred

T-Safe 380A  QL

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Prescribe generically - not to be prescribed by brand.

12 hour missed pill window with higher risk of irregular bleeding

Option for endometriosis

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Desorex, Zelletta, Feanolla, Cerelle, Desomono, Cerazette, Lovima -Do NOT prescribe by brand

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Preferred brands: Gedarel 20/150, Bimezza, Gedarel 30/150, Cimizt

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Mercilon, Marvilon - Not recommended for new initiations. Exisitng patients may remain on this brand.

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Preferred brands: Yacella, Dretine

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Lucette, Ellanite, Yasmin, Eloine - Not recommended for new initiations. Exisitng patients may remain on this brand.

 
Links :
Indication :
Status :
Green
Formulations :
  • Vaginal insert
Restrictions / Comments:

Important

Note a cost-effective choice. Consider only if compliance / swallowing difficulties / malabsorption with oral CHC and LARC is unsuitable.

SyreniRing is lower cost than NuvaRing and does not require refrigeration

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Preferred brands: Millinette 20/75, Millinette 30/75

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Sunya, Akizza 75/20, Katya

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Femodette, Femodene, Akizza 75/30 - Not recommended for new initiations. Exisitng patients may remain on this brand.

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Microgynon 30 ED, TriRegol, Logynon, Logynon ED

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Preferred brands = Levest, Rigevidon, Maexeni,

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Ovranette / Ambelina / Microgynon 30 - not for new initiations. Existing patients may remain on current brand.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Elevin brand is not a cost effective option. 

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

 
Links :
Indication :
Status :
Green
Formulations :
  • Implant
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Levosert

 
Links :
Indication :
Status :
Green
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Mirena

May be particularly useful in women with heavy menstrual bleeding requiring (reversible) contraception.

Option for polycystic ovary syndrome.

RSFT: 2nd line for contraception and heavy menstrual bleeding for use when Benilexa is unsuitable of unavailable.

RSFT: Endometrial protection as part of HRT in both peri and postmenopausal women

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important

Norgeston

progesterone only pill, POP

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Jaydess 13.5mg

SASH: Jaydess is restriced to those patients who require a smaller size / lower dose of levonorgestrel

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Kyleena 19.5mg.

RSFT: Kyleena should only be used in nulliparous patients under 25 years onld and those unable to use the alternative devices.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Benilexa One Handed

RSFT: 1st line for contraception and treatment of heavy menstrual bleeding for females between the ages of 18 and 45 years.

Option for polycystic ovary syndrome. May be particularly useful in women wih hevy menstrual bleeding requiring (reversible) contraception.

 
Links :
Indication :
Status :
Green
Formulations :
  • Injection
Restrictions / Comments:

Important

Sayana Press

Patients may be trained to self-administer Sayana Press

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Pre-filled syringe
Restrictions / Comments:

Important

Depo Provera

CSM advice: Depo-Provera should only be used when other methods of contraception are inappropriate. Benefits of using medroxyprogesterone acetate beyond 2 years should be evalated against risk.

Women with risk factors for osteoporosis should consider alternative methos of contraception.

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

3 hour missed pill window

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Injection
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Noristerat 200mg/1ml solution for injection

 

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

2nd line after desogestrel. Caution - may have different drug interactions to other progestogen-only pills.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Not a cost-effective choice. Consider only if compliance issues/swallowing difficulties/malabsorption with oral CHC and LARC is unsuitable.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Not recommended for new initiations. Existing patients may remain on this brand.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Not recommended for new initiations. Existing patients may remain on this brand.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

Not recommended for new initiations. Exisitng patients may remain on this brand.

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :